TABLE 2.
Tumor features
| Sarcomatoid (n = 15) | Non‐sarcomatoid (n = 75) | p | |
|---|---|---|---|
| AJCC stage, n (%) | 1.000 | ||
| I | 6 (40.0) | 30 (40.0) | |
| II | 4 (26.7) | 20 (26.7) | |
| III | 2 (13.3) | 10 (13.3) | |
| IV | 3 (20.0) | 15 (20.0) | |
| BCLC stage, n (%) | 0.881 | ||
| 0 | 1 (6.7) | 3 (4.0) | |
| A | 8 (53.3) | 34 (45.3) | |
| B | 1 (6.7) | 6 (8.0) | |
| C | 5 (33.3) | 32 (42.7) | |
| Differentiation grade, n (%) | <0.001 | ||
| Well | 0 (0) | 2 (2.7) | |
| Moderate | 0 (0) | 36 (48.0) | |
| Poor | 8 (53.3) | 36 (48.0) | |
| Undifferentiated | 7 (46.7) | 1 (1.3) | |
| Tumor size, n (%) | 0.086 | ||
| <2 cm | 1 (6.7) | 6 (8.0) | |
| 2–5 cm | 3 (20.0) | 37 (49.3) | |
| >5 cm | 11 (73.3) | 32 (42.7) | |
| Tumor number, n (%) | 0.120 | ||
| Single | 12 (80.0) | 44 (58.7) | |
| Multiple | 3 (20.0) | 31 (41.3) | |
| α‐fetoprotein, n (%) | 0.200 | ||
| <20 ng/ml | 10 (66.7) | 36 (48.0) | |
| 20–400 ng/ml | 4 (26.7) | 18 (24.0) | |
| >400 ng/ml | 1 (6.7) | 21 (28.0) | |
| Tumor location, n (%) | 0.673 | ||
| Left lobe | 2 (13.3) | 17 (23.0) | |
| Right lobe | 12 (80.0) | 51 (68.9) | |
| Both lobes | 1 (6.7) | 6 (8.1) | |
| Vascular invasion, n (%) | |||
| Macro‐ | 3 (20.0) | 14 (18.7) | 0.904 |
| Micro‐ | 3 (20.0) | 25 (33.3) | 0.309 |
| Adjuvant therapy, n (%) | |||
| TACE | 7 (46.7) | 43 (57.3) | 0.448 |
| Sorafenib | 1 (6.7) | 3 (4.0) | 0.647 |
Abbreviation: TACE, Transcatheter arterial chemoembolization.